GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lucira Health Inc (OTCPK:LHDXQ) » Definitions » EBITDA Margin %

Lucira Health (Lucira Health) EBITDA Margin % : -361.03% (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Lucira Health EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Lucira Health's EBITDA for the three months ended in Sep. 2022 was $-124.2 Mil. Lucira Health's Revenue for the three months ended in Sep. 2022 was $34.4 Mil. Therefore, Lucira Health's EBITDA margin for the quarter that ended in Sep. 2022 was -361.03%.


Lucira Health EBITDA Margin % Historical Data

The historical data trend for Lucira Health's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucira Health EBITDA Margin % Chart

Lucira Health Annual Data
Trend Dec18 Dec19 Dec20 Dec21
EBITDA Margin %
- - -13,760.22 -65.70

Lucira Health Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -175.08 -10.74 17.10 -74.32 -361.03

Competitive Comparison of Lucira Health's EBITDA Margin %

For the Medical Devices subindustry, Lucira Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lucira Health's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lucira Health's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Lucira Health's EBITDA Margin % falls into.



Lucira Health EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Lucira Health's EBITDA Margin % for the fiscal year that ended in Dec. 2021 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2021 )/Revenue (A: Dec. 2021 )
=-61.136/93.055
=-65.70 %

Lucira Health's EBITDA Margin % for the quarter that ended in Sep. 2022 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2022 )/Revenue (Q: Sep. 2022 )
=-124.159/34.39
=-361.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lucira Health  (OTCPK:LHDXQ) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Lucira Health EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Lucira Health's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lucira Health (Lucira Health) Business Description

Traded in Other Exchanges
N/A
Address
1412 62nd Street, Emeryville, CA, USA, 94608
Lucira Health Inc is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. It has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and user-friendly test kit that is powered by two AA batteries and fit in the palm of a hand. The company's initial focus is within respiratory diseases, and initially for COVID-19 and influenza Types A and B indications.
Executives
Anthony Joseph Allen officer: Chief Operations Officer 1412 62ND STREET, EMERYVILLE CA 94608
Epq Llc, Lcovd Safe Ps other: Less than 10% owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Chad Boeding other: CEO of 10% owner ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Epiq Capital Group, Llc 10 percent owner ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Epq Llc, Lcovd Ps 10 percent owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Lflu Ps other: Less than 10% owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Ltest Ps other: Less than 10% Owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Richard Clavano Narido officer: Interim CFO 12 HANSEN CT, MORAGA CA 94556
Ghazi Kashmolah officer: Ex. VP &Chief Quality Officer 1412 62ND STREET, EMERYVILLE CA 94608
Kevin Walter Collins officer: Chief Revenue Officer C/O LUCIRA HEALTH, INC., 1412 62ND STREET, EMERYVILLE CA 94608
Dan George officer: CFO and Treasurer 1412 62ND STREET, EMERYVILLE CA 94608
Erik T. Engelson director, officer: President and Chief Executive 1412 62ND STREET, EMERYVILLE CA 94608
Debkishore Mitra director, officer: Chief Technology Officer 1412 62ND STREET, EMERYVILLE CA 94608
Tamanna Prashar officer: Vice President 1412 62ND STREET, EMERYVILLE CA 94608
Alison Mccauley director C/O LUCIRA HEALTH, INC., 1412 62ND STREET, EMERYVILLE CA 94608